Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.48 |
| ▸ | TYR | P14679 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.43 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.43 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.43 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16355887 | 0.89 | IGF1R (0.47) | ALOX5PLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL3242232 | 0.89 | ESR1 (0.56) | TYRHSD17B10ESR1ESR2 | |
| SCHEMBL16355886 | 0.88 | IGF1R (0.46) | ALOX5PLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL4208352 | 0.86 | TYR (0.58) | TYRHSD17B10HPGDESR1ESR2 | |
| SCHEMBL2471139 | 0.85 | HSD17B3 (0.48) | ALOX5HSD17B3TYRHSD17B10OPRK1 | |
| SCHEMBL11718847 | 0.83 | ALOX5 (0.67) | ALOX5HSD17B3HSD17B10HPGD | |
| SCHEMBL29492432 | 0.81 | TYR (0.72) | ALOX5HSD17B3TYR | |
| SCHEMBL70564 | 0.81 | TYR (0.72) | ALOX5HSD17B3TYR | |
| SCHEMBL16355701 | 0.80 | ALOX5 (0.50) | ALOX5HSD17B3TYROPRK1ESR2 | |
| Water SCHEMBL28104515 | 0.79 | TYR (0.69) | ALOX5HSD17B3TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9199927-B2 | Guanidinobenzoic acid compound | ASTELLAS PHARMA INC. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20140378459-A1 | GUANIDINOBENZOIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378459-A1 | GUANIDINOBENZOIC ACID COMPOUND | SERPINB1, REN, SPINT2 | ALOX5 1562/4885HSD17B3 2747/4885TYR 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.